Breaking News


Airgas, BlackRock, DineEquity, Gymboree: U.S. Equity Movers

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 10:45 a.m. in New York.

Airgas Inc. (ARG US) advanced 2.6 percent to $69.61 after rising to $70, the highest price since at least December 1986. The industrial-gas distributor plans to appeal a court ruling that would allow its next annual meeting to be held in January. Airgas is fighting a $5.5 billion takeover bid by Air Products & Chemicals Inc. (APD US), which may use the ruling to take control of Airgas at the January meeting.

Alexza Pharmaceuticals Inc. (ALXA US) slumped 52 percent to $1.44, its biggest decline since its March 2006 initial public offering. The Mountain View, California-based company said the U.S. Food and Drug Administration rejected its experimental treatment for use against agitation in patients with schizophrenia or bipolar disorder.

Allos Therapeutics Inc. (ALTH US) fell 7.5 percent to $4.23 after sliding 8.5 percent, the most intraday since July 28. The drugmaker’s lymphoma drug Folotyn appeared at least as effective as Roche Holding AG’s (ROG VX) Tarceva for lung cancer, and may help patients live longer, a clinical trial showed.

BlackRock Inc. (BLK US) increased 1 percent to $176.22 after rising to $177.80, the highest intraday price since May 10. The world’s largest asset-management firm’s Taiwan unit expects assets under management to grow 10 percent a year for the next four years, according to Chang Lin-yun, head of the unit.

The firm aims to start an Asian fixed income fund next year, and plans to sell an international equity fund in the first quarter of next year, Chang said.

Chesapeake Energy Corp. (CHK US) advanced 3.3 percent to $23.81 after climbing as much as 5.5 percent, the most intraday since June 3. Cnooc Ltd. (883 HK) will pay $1.08 billion for a one-third stake in the second-biggest producer of U.S. natural gas’s Eagle Ford shale project in Texas, in the largest acquisition of a U.S. oil and gas asset by a Chinese company.

Citrix Systems Inc. (CTXS US) slumped 4.1 percent to $57.20, the biggest decline in the S&P 500. Credit Suisse Group AG analyst Philip Winslow said in a note the software maker’s sales were slower in the third quarter than in the second quarter. Credit Suisse expects a sequential decline in Citrix’s XenDesktop bookings and license revenue, he wrote.

DineEquity Inc. (DIN US) rose 2.4 percent to $47.86 after hitting $48.54, the highest intraday price since May 2008. The restaurant company said it will sell 20 of its Applebee’s Neighborhood Grill & Bar restaurants located in the Roanoke and Lynchburg markets of Virginia to Apple Investors Group LLC.

Gymboree Corp. (GYMB US) surged 23 percent to $64.97, the most intraday since April 2009. The children’s apparel retailer has agreed to be acquired by Bain Capital LLC for $65.40 a share in cash, or $1.8 billion.

ImmunoGen Inc. (IMGN US) rose 5.9 percent to $7.52 after jumping 9.9 percent, the most intraday since Aug. 30. The maker of anticancer drugs said Novartis AG will pay it a $45 million fee for exclusive rights to its technology that uses antibodies to deliver cancer drugs against specific tumor types. ImmunoGen may receive more than $200 million for each cancer drug that results from the agreement, the company said in a statement.

Sherwin-Williams Co. (SHW US) fell 2.2 percent to $71.88 after slipping 3.2 percent, the most intraday since July 22. The largest U.S. paint retailer was cut to “equalweight” from “overweight” at Stephens Group Inc. The price estimate was cut to $78 from $80.

Warner Chilcott Plc (WCRX US) jumped 6.8 percent to $23.79 after surging 9.3 percent, the most intraday since August 2009. The pharmaceutical company focused on women’s health care announced the U.S. Food and Drug Administration approved its next generation Actonel for the treatment of osteoporosis.

To contact the reporter on this story: Inyoung Hwang in New York at

To contact the editor responsible for this story: Nick Baker at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.